For the study, researchers administered the combination antiviral therapy — consisting of oseltamivir, ribavirin and amantadine — twice a day to 239 flu patients seeking treatment in an ambulatory setting. The team treated another 394 flu patients with oseltamivir alone.
After three days of treatment, 40 percent of the combo cohort displayed viral shedding, opposed to 50 percent of the participants treated with Tamiflu. However, neither cohort experienced a difference in symptom reduction.
“Although combination treatment showed a significant decrease in viral shedding at day three relative to monotherapy, this difference was not associated with improved clinical benefit,” concluded the study’s authors. “More work is needed to understand why there was no clinical benefit when a difference in virological outcome was identified.”
More articles on infection control:
Positive mood on day of flu shot may boost viral protection, study finds
Antibiotic use, chronic liver disease linked to C. diff recurrence
Top 10 infection control stories, Sept. 18-22
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
